Chris Viehbacher made the following comment (see Fierce Biotech) when asked yesterday about Sanofi's pursuit of Genzyme and the ongoing CVR talks revolving around Genzyme's Lemtrada for MS.
"There are still gaps but I think we have made some progress. Whether that is enough to entirely close the gap we will have to wait and see. But, I think we would expect that given the forecasts, which we don't necessarily share, that it could be significant value to Genzyme shareholders"
Posted by Bruce Lehr Jan 26th 2011.